- Previous Close
0.0140 - Open
0.0140 - Bid 0.0140 x 62500000
- Ask 0.0150 x 81500000
- Day's Range
0.0140 - 0.0150 - 52 Week Range
0.0110 - 0.0220 - Volume
98,354 - Avg. Volume
97,448 - Market Cap (intraday)
19.189M - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings Date May 22, 2025 - May 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity. The company offers BLIS K12, an oral probiotic supplement to support ear, nose, and throat health, as well as for enhancing immunity and bad breath; BLIS M18, an oral probiotic to support teeth and gums health; and BLIS Q24, a probiotic supplement to balance the skin microbiome, restoring the health, clarity, and radiance. It has operations in New Zealand, Asia Pacific, Europe, the Middle East, Africa, and North America. The company was incorporated in 2000 and is based in Dunedin, New Zealand.
www.blis.co.nzRecent News: BLT.NZ
View MorePerformance Overview: BLT.NZ
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BLT.NZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BLT.NZ
View MoreValuation Measures
Market Cap
17.91M
Enterprise Value
9.40M
Trailing P/E
11.67
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.44
Price/Book (mrq)
1.53
Enterprise Value/Revenue
0.80
Enterprise Value/EBITDA
4.32
Financial Highlights
Profitability and Income Statement
Profit Margin
12.09%
Return on Assets (ttm)
5.95%
Return on Equity (ttm)
14.12%
Revenue (ttm)
12.78M
Net Income Avi to Common (ttm)
1.54M
Diluted EPS (ttm)
0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
8.92M
Total Debt/Equity (mrq)
4.13%
Levered Free Cash Flow (ttm)
364.88k